ReviewFrontiers in microbiology2026
Scorpion venom as a source of new antimicrobial agents.
Review in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The escalating global threat of antimicrobial resistance necessitates urgent discovery of novel therapeutic agents. Scorpion venom, a complex cocktail of bioactive molecules, has emerged as a promising reservoir of antimicrobial peptides (AMPs) with potent activity against multidrug-resistant pathogens. This review comprehensively examines the structural and functional diversity of scorpion-derived AMPs and their therapeutic potential. Scorpion venom AMPs exhibit remarkable structural heterogeneity. Their physicochemical properties, characterized by cationic charge, amphipathicity, and α-helical or β-sheet conformations, underpin their antimicrobial efficacy. These peptides demonstrate broad-spectrum antimicrobial activity encompassing Gram-positive and Gram-negative bacteria, fungi, viruses, and parasites. Mechanistically, scorpion AMPs employ multifaceted strategies including membrane disruption through pore formation or carpet-like mechanisms, cell wall synthesis inhibition, intracellular interference with DNA replication and protein synthesis, biofilm dispersion, immunomodulation, and ion channel modulation. This polypharmacological approach has been proposed to lower the risk for resistance development relative to conventional antibiotics, though this remains to be comprehensively validated across diverse scorpion AMPs. Despite their therapeutic promise, challenges persist regarding cytotoxicity, proteolytic instability, and high production costs. However, rational engineering strategies, including sequence truncation, D-amino acid substitution, cyclization, and hybrid peptide design, are advancing clinical viability. Notable candidates have demonstrated exceptional potency in preclinical models. This review synthesizes current knowledge on scorpion venom AMPs, highlighting their advantages over traditional antibiotics and outlining optimization strategies. Future research directions emphasize structure-activity relationship studies, novel delivery systems, and comprehensive toxicological profiling. Scorpion venom represents an underexploited natural resource that may yield next-generation antimicrobial therapeutics critical for combating the growing threat of drug-resistant infections.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.